BBA57-Mediated Borrelial Persistence, Genesis of Inflammation and Immunity
BBA57-Mediated Borrelial Persistence, Genesis of Inflammation and Immunity
批准号:
8858229
负责人:
UTPAL PAL
金额:
$38.0万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-02-01 至 2020-01-31
关键词:
Antibiotic TherapyAntibody ResponseAntigensArthritisAsiaAwarenessBacteriaBiologyBorreliaBorrelia burgdorferiCellsCenters for Disease Control and Prevention (U.S.)Communicable DiseasesComplexDataDefectDevelopmentDiagnosisElementsEpitopesEuropeExhibitsGene ClusterGenerationsGenesGenomeGoalsHistocompatibility Antigens Class IIHumanImmunityImmunizationIncidenceInfectionInflammationInflammatoryInflammatory ResponseJointsJournalsLife Cycle StagesLightLipoproteinsLyme ArthritisLyme DiseaseMammalsMeasuresMediatingMediator of activation proteinMembrane ProteinsMolecularMusNatural ImmunityOrder SpirochaetalesOutcomePathogenesisPharmaceutical PreparationsPhasePhenotypePrevention MeasuresPreventiveProcessProductionProteinsPublished CommentPublishingRecombinantsRecruitment ActivityReportingResistanceRoleSpirochaetales InfectionsSumSurfaceTestingTherapeuticTick-Borne InfectionsTicksUnited StatesUp-RegulationVaccinesVector-transmitted infectious diseaseVirulenceWorkantimicrobial peptidebasecell typechemokinecombatdisorder preventioneditorialenzooticin vivomicrobialmicrobicidemutantneutrophilnovelparalogous genepathogenpublic health relevanceresponsetherapeutic targettransmission processtransmission-blocking vaccinevaccine candidatevaccine developmentvector
中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lyme borreliosis is a prevalent vector-borne disease in the United States, Europe, and parts of Asia, caused by the bacterial pathogen Borrelia burgdorferi. The infection can be difficult to diagnose, and a human vaccine is currently unavailable. The application will study how BBA57 - a unique borrelial gene product and newly identified virulence determinant of unknown function - contributes to multiple aspects of microbial infectivity and pathogenesis and also assess its efficacy in generating protective host immunity against infection. Although many bacterial pathogens have evolved measures to limit host microbicidal responses, relatively little is known about how B. burgdorferi evade innate immunity as they transmit to mammalian hosts. Based on our published and new preliminary data, we hypothesize that BBA57, an in-vivo induced, surface-exposed outer membrane protein, facilitates spirochete defense against specific host innate immune responses and that the antigen induces production of neutrophil-recruiting chemokines in joint cells, which triggers arthritis. Upon successful completion of the proposed work, we will be able to demonstrate that BBA57 represents, to the best of our knowledge, the first example of a B. burgdorferi protein that confers resistance to specific antimicrobial peptides (AMPs), thereby promoting establishment of early B. burgdorferi infection in murine hosts. We have three major goals. First, we will examine how BBA57 contributes to spirochete AMP resistance during early infection. Second, we will identify the joint cell type(s) that are responsible for BBA57-mediated chemokine responses critical for arthritis. Finally, as BBA57 is also dramatically produced in ticks, we will explore the role of the protein in perpetuating the vector phases of the borrelial lfe cycle, including tick-to-mouse transmission, and based on our preliminary immunization data, we will assess its potential as a new candidate antigen for generation of protective host immunity. In sum, these studies will contribute to better understanding the infectivity and pathogenesis of B. burgdorferi and help in the development of novel preventive and therapeutic measures to combat infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multivalent Tick-Microbe targeted Lyme disease vaccines
-
批准号:10442534
-
项目类别:
-
资助金额:$71.7万
-
财政年份:2020
-
负责人:UTPAL PAL
-
依托单位:
Multivalent Tick-Microbe targeted Lyme disease vaccines
-
批准号:10059039
-
项目类别:
-
资助金额:$70.8万
-
财政年份:2020
-
负责人:UTPAL PAL
-
依托单位:
Multivalent Tick-Microbe targeted Lyme disease vaccines
-
批准号:10219933
-
项目类别:
-
资助金额:$71.29万
-
财政年份:2020
-
负责人:UTPAL PAL
-
依托单位:
Cross-Species Immunity Signals Impacting Persistence of Tick-Borne Pathogens
-
批准号:9976334
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2018
-
负责人:UTPAL PAL
-
依托单位:
Cross-Species Immunity Signals Impacting Persistence of Tick-Borne Pathogens
-
批准号:10222517
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2018
-
负责人:UTPAL PAL
-
依托单位:
Administrative Core
-
批准号:9976329
-
项目类别:
-
资助金额:$15.37万
-
财政年份:2018
-
负责人:UTPAL PAL
-
依托单位:
Administrative Core
-
批准号:10222515
-
项目类别:
-
资助金额:$15.37万
-
财政年份:2018
-
负责人:UTPAL PAL
-
依托单位:
Administrative Core
-
批准号:10440405
-
项目类别:
-
资助金额:$15.37万
-
财政年份:2018
-
负责人:UTPAL PAL
-
依托单位:
Cross-Species Immunity Signals Impacting Persistence of Tick-Borne Pathogens
-
批准号:10440407
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2018
-
负责人:UTPAL PAL
-
依托单位:
BBA57-Mediated Borrelial Persistence, Genesis of Inflammation and Immunity
-
批准号:8996710
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2015
-
负责人:UTPAL PAL
-
依托单位:
NDV-vectored Lyme disease vaccines
-
批准号:8511948
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2013
-
负责人:UTPAL PAL
-
依托单位:
NDV-vectored Lyme disease vaccines
-
批准号:8605523
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2013
-
负责人:UTPAL PAL
-
依托单位:
BORRELIA GENE PRODUCTS CRITICAL FOR NATURAL INFECTION CYCLE
-
批准号:8917085
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Borrelia gene products critical for natural infection cycle
-
批准号:10659166
-
项目类别:
-
资助金额:$48.67万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Borrelia gene products critical for natural infection cycle
-
批准号:7728780
-
项目类别:
-
资助金额:$37.5万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Borrelia gene products critical for natural infection cycle
-
批准号:7881501
-
项目类别:
-
资助金额:$37.13万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Borella Gene Products Critical For Natural Infection Cycle
-
批准号:8662997
-
项目类别:
-
资助金额:$35.72万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Borrelia gene products critical for natural infection cycle
-
批准号:10157412
-
项目类别:
-
资助金额:$49.85万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Administrative Supplement: Borrelia gene products critical for natural infection cycle
-
批准号:10626479
-
项目类别:
-
资助金额:$22.32万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
Borrelia gene products critical for natural infection cycle
-
批准号:8281505
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:UTPAL PAL
-
依托单位:
海外基金